Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win

TLDR

• NTLA stock initially surged 25% on trial anticipation before falling 3% after results dropped
• Phase 3 HAELO trial met its primary endpoint and all key secondary endpoints
• A single dose of lonvo-z reduced hereditary angioedema attacks by 87% vs placebo
• Intellia has begun a rolling BLA submission to the FDA
• Potential U.S. launch is targeted for the first half of 2027, if approved

Intellia Therapeutics stock had a wild Monday. It jumped 25% as investors braced for Phase 3 data, then gave back those gains and more, closing down 3% once the results were actually out.

Intellia Therapeutics, Inc., NTLA

The data itself was strong. The HAELO trial for lonvoguran ziclumeran — or lonvo-z — met its primary endpoint and every key secondary endpoint.

Patients who received the treatment saw hereditary angioedema attacks drop by 87% compared to placebo. The mean monthly attack rate came in at 0.26 for the treatment arm versus 2.10 in the placebo group.

The trial enrolled 80 patients. Fifty-two received lonvo-z, and 28 received placebo. Most patients who got the treatment stayed free from attacks and ongoing therapy throughout the six-month evaluation window.

As of the February 10 data cutoff, all lonvo-z patients remained free from long-term prophylaxis therapy. That’s a clean result for a one-time treatment.

The safety profile held up too. The most common adverse events were infusion-related reactions, headache, and fatigue. All reported adverse events were mild or moderate — no serious adverse events were recorded in the lonvo-z arm.

What Happens Next

Intellia has already kicked off a rolling biologics license application with the FDA. If approved, the company is targeting a U.S. launch in the first half of 2027.

The therapy works by inactivating the KLKB1 gene to permanently lower kallikrein and bradykinin levels. It’s administered in an outpatient setting as a one-time infusion.

This is also a landmark moment in gene editing. The HAELO trial represents the first global Phase 3 data readout for an in vivo gene editing therapy.

More data from the trial will be presented at the 2026 European Academy of Allergy and Clinical Immunology Congress in June.

The Numbers Behind NTLA

Intellia carries a market cap of around $1.61 billion. Its GF Score stands at 70 out of 100, with a Growth Rank of 7/10 but a Profitability Rank of just 1/10.

The P/S ratio is 21.93, reflecting a market pricing in significant future growth rather than current earnings.

Insider activity has been light. No purchases in the past three months, but two selling transactions totaling 1,818 units were recorded.

The company has collaborations with Regeneron and Novartis to support its broader pipeline, which also includes therapies for ATTR amyloidosis and sickle cell disease.

Additional HAELO clinical data is set to be presented at the EAACI Congress in June 2026.

The post Buy the Rumor, Sell the News: Intellia (NTLA) Falls After Landmark Phase 3 Win appeared first on CoinCentral.